Sunteți pe pagina 1din 2

Drug Study

Drug Name
Generic
bevacizuma
b
Trade
Avastin

Classificati
on
Antineopla
stic

Indications

Mechanism of Action

First or second
line treatment,
with
fluorouracilbased
chemotherapy,
for metastatic
colon or rectal
cancer

A recombinant
humanized vascular
endothelial growth
factor inhibitor.

Route/Frequency/Do
sage
5 mg/kg IV every 14
days

Adverse Reactions

Drug Interaction

CNS: asthesia,
dizziness,
headache,
abnormal gait,
confusion, pain,
syncope
CV: intraabdominal
thrombosis,
hypertension,
thromboembolism,
deep vein
thrombosis, heart
failure,
hypotension
EENT: epistaxis,
excess lacrimation,
gum bleeding,
taste disorder,
voice alteration
GI: anorexia,
constipation,
diarrhea,
dyspepsia,
flatulence,
stomatitis,
vomiting, GI
hemorrhage,
abdominal pain,
colitis, dry mouth,
nausea
GU: vaginal
hemorrhage,

None reported

Nursing
Consideration
RPLS-associated
symptoms may
occur 16 hours to 1
year after starting
the drug. It can only
be confirmed via
MRI.
Hypersensitivity
reactions may occur
during infusion.
Stop drug for patients
developing
nephrotic
syndrome, severe
hypertension,
hypertensive crisis,
serious bleeding, GI
perforation, or
wound dehiscence.

proteinuria,
urinary urgency
Hematologic:
leukopenia,
neutropenia,
thrombocytopenia
Metabolic:
hypokalemia,
weight loss,
bilirubinemia
Musculoskeletal:
back pain, myalgia
Respiratory:
hemoptysis,
dyspnea, upper
respiratory tract
infection
Skin: alopecia,
dermatitis,
discoloration, dry
skin, exfoliative
dermatitis, nail
disorder, skin ulcer